Analysts think SONN stock price could increase by 2592%
Aug 30, 2024, 6:25 AM
0.00%
What does SONN do
Sonnet BioTherapeutics Holdings, a clinical stage biotech based in Princeton, New Jersey, specializes in biologic medicines and has developed the FHAB technology for improved drug delivery in cancer treatment. Its lead assets include SON-1010 for solid tumors and SON-080 for chemotherapy-induced peripheral neuropathy.
4 analysts think SONN stock price will increase by 2591.87%. The current median analyst target is $18.87 compared to a current stock price of $0.70. The lowest analysts target is $7.07 and the highest analyst target is $31.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.